Rednose Inv

Q3 results are in and here are the highlights: - We’re growing fast and efficient. Revenue is up 49% year over year. Adjusted EBITDA is up 53%. Increasing confidence we can meet and surpass 2030 targets of $6.5B and $1.3B in Adj. EBITDA. - Growth is becoming more diversified. Hims is growing 40% yoy excluding the generic PRN business we are shifting away from. Hers is growing high double/triple digits toward north of $1B in revenue next year. – The best offerings in healthcare are coming to the table given the scale of our consumer platform. From advanced diagnostics to early stage biotech. We’re leaning in hard here to curate the best, at affordable prices. – As we scale, we’re passing savings back to the consumer. We started the year with ~400,000 sq ft. of verticalized facilities, and expect to end the year at north of 1 million, with consumers as the true beneficiaries of our expanding scale. Gold standard infrastructure + FDA registered facilities & GreenList suppliers for GLP-1s = real wins for consumers. – New categories like Testosterone and Menopause expected to be growth drivers next year. Great early signals and product market fit. Now we’re focused on optimizing the engines. - Comprehensive lab testing is on track to launch by year end at a fraction of the cost that this level of advanced testing can run today. Hundreds, not thousands. Over time we’ll verticalize further this lab infrastructure to bring the cost as low as possible. – Longevity is going live next year. Expected to eventually include peptides, coenzymes, GLP/GIP, supplements and tracking. If the rich and famous have access to these levels of cutting edge precision therapies, we want you to have it also. Our California facilities are in full-motion onshoring R&D for core peptides. – International is on deck. Canada will be live soon, and we’re in active conversations with the leading generics manufacturers for when semaglutide will be available in Canada and Brazil in generic form in 2026. Continuing investments in the UK & Germany, and looking at other international markets like Australia & other Latin American and Asian markets. Our goal hasn’t changed: help the world feel great. ————————— Read more here: investors.hims.com/files/doc… Important info here: news.hims.com/disclaimers/ca…

We just shared our Q2 results and I believe the quarters to come will bring more exciting growth as we show the industry that the future of healthcare is scalable, data-driven, and personal. Read more here: news.hims.com/newsroom/inves…

We just shared our Q1 results. And our 2030 target: $6.5B in revenue, $1.3B in adjusted EBITDA. We're entering a new era of growth: deeper personalization, broader impact, and faster execution. The foundation is set. The roadmap is clear. We're just getting started.